Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLC

Authors
Category Primary study
JournalCLINICAL LUNG CANCER
Year 2026
This article has no abstract
Epistemonikos ID: cdedd63252f34872babac06ec9e8567259b2a254
First added on: Jan 24, 2026